Title:
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Indication:
Lymphoma
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients with Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I
Title:
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: II
Title:
An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis
Indication:
Hematology- Myelofibrosis
Location:
Texas Oncology-Tyler
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Blood Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Title:
Registry study with Breast Cancer Index
View
Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorÂ-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)
View
Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)
View
Description: SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- MBC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigators Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph3 HER2/neu BC (FLAMINGO-01)
View
Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Breast Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Carcinoid
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Carcinoid
Location:
Texas Oncology-Tyler
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Cervical Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Cervical Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph2 Epidemi Colon Cancer
View
Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
Ph2 RO7198457 CRC ctDNA+ Post Resection
View
Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Colon Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
INCMGA00012 Endo Cancer
View
Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph3 Selin P53 Endo Carcinoma
View
Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
View
Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Hematologic
Location:
Texas Oncology-Tyler
Phase: II
Title:
PATHFINDER 2 Early Detection Test
View
Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Indication:
Hematologic
Location:
Texas Oncology-Tyler
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Hematologic
Location:
Texas Oncology-Tyler
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Tyler
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Leukemia
Location:
Texas Oncology-Tyler
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Leukemia
Location:
Texas Oncology-Tyler
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Liver Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Liver Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Liver Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Biomarker status NSCLC
View
Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph1 SPYK04 Solid Tumors
View
Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: (FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: I
Title:
LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.
View
Description: GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph2 Epco r/r B-Cell Lymph out pt
View
Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
Indication:
Lymphomas
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Melanoma
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Melanoma
Location:
Texas Oncology-Tyler
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph2 Dara Lena Dexa (DRd) MM I
View
Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)
Indication:
Myelomas
Location:
Texas Oncology-Tyler
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Myelomas
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph1 SPYK04 Solid Tumors
View
Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
Ph1/2 Azeliragon refrac to 1st Line Pancreatic
View
Description: A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer (CAN-201)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph3 Abema +Abira +Predn mHSPC (Cyclone3)
View
Description: CYCLONE 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)
Indication:
Prostate Cancer
Location:
Texas Oncology-Tyler
Phase: III
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph2 Epidemi Colon Cancer
View
Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
Ph2 RO7198457 CRC ctDNA+ Post Resection
View
Description: A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)
Indication:
Rectal Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Rectal Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
Ph1b-XL092 Immun Onco mST
View
Description: A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002)
Indication:
Renal Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Renal Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Skin Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I
Title:
PATHFINDER 2 Early Detection Test
View
Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: IV
Title:
Ph1b/2 BEMA FGFR2b ST Basket Trial
View
Description: A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I/II
Title:
Ph1 SPYK04 Solid Tumors
View
Description: A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: I
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: II
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Solid Tumors
Location:
Texas Oncology-Tyler
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer andNon-Cancer Subjects for Validation of a Novel Blood-Based Multi-CancerScreening Test (HH-PRT-0001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Tyler
Phase: IV
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Tyler
Phase: II/III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Tyler
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Tyler
Phase: I